The Investigational New Drug Program of the Canadian Cancer Trials Group
Kingston, Ontario
Joined October 2022
- Tweets164
- Following91
- Followers44
- Likes143
Congratulations @Philippe_Bedard on the ESMO-TAT Honorary Award 2025 @CDNCancerTrials
Academic consortia around the world linkedin.com/posts/jennyjial…
ENA 2024 is in Barcelona from 23-25 October! 🌟 Don’t miss out on the top-notch sessions and dynamic networking opportunities. Register today #ENASymp24 eortc.org/ena
@peters_solange @ChristinaBYap @danieltanmd @GPentheroudakis @FAndreMD @curijoey @DrIgMelero @PaoloNuciforo @brainstrust @DMBranco
MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO
sciencedirect.com/science/ar…
MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO
sciencedirect.com/science/ar…
IND Program CCTG retweeted
🎙️@PBarataMD of @UHhospitals and @lillian_siu of @pmcancercentre discuss recent state-of-the-art advancements in cancer vaccine development on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/po…
IND Program CCTG retweeted
The @FDA's recent draft guidance on #DiversityActionPlans for clinical trials is an important step towards more inclusive and representative trials. Friends CEO Jeff Allen recently spoke to @RAPSorg about this guidance and its importance. raps.org/news-and-articles/n…
IND Program CCTG retweeted
Register by September 4 to get the lowest available rates for the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (October 23-25, Barcelona, Spain), chaired by @VriesElisabeth, @TimGreten, and Timothy A. Yap.
bit.ly/3VYkhbe
#ENASymp24
IND Program CCTG retweeted
Nerve cells were considered bystanders in the spread of #cancer. Dr. Sebastien Talbot has revealed that certain nerve cells are key to tumour survival. Learn more about his research supported by @azrielifdn & @BrainCanada: bit.ly/4f03SvK @queensuResearch @QueensuSCRI
IND Program CCTG retweeted
Did you know smoking tobacco increases the risk of developing 18 types of cancers? Learn about ways to reduce the burden of cancer in the @AACR #CancerProgressReport. bit.ly/3zE6YoT
IND Program CCTG retweeted
Explore the forefront of thoracic oncology at #WCLC24! With 6,000+ delegates from over 100 countries, it is a must-attend event for professionals in the field of lung and other thoracic cancers. Register by July 29 at wclc2024.iaslc.org/37mh
IND Program CCTG retweeted
July is #SarcomaAwarenessMonth. Join us in raising awareness and supporting those affected by the battle against Sarcoma. #CCTG is inspired by the strength and resilience of all patients and families. We are committed to advancing research and helping improve lives.
IND Program CCTG retweeted
Congratulations to former @cancersociety board member Dr Tony Fields, who served as president of the National Cancer Institute of Canada (CCS’s research arm before integration). A well-deserved recognition for an outstanding career and leadership!
The CMA is pleased to announce this year’s CMA Awards recipients. These 13 passionate and determined individuals are reimagining the future of health care. Congratulations to all! 👏 cma.ca/get-involved/awards/2…
IND Program CCTG retweeted
🌟Attention students and trainees looking for a postdoc experience at @theNCI: The NCI Cancer Prevention Fellowship Program is accepting applications through Aug 1!
Don’t miss this opportunity! cpfp.cancer.gov
This quoted post is unavailable.
IND Program CCTG retweeted
#Breaking: Today, we provided an update on the Phase II/III trial evaluating our investigational anti-#TIGIT cancer immunotherapy in advanced non-squamous NSCLC. Learn more: gene.com/media/press-release…
IND Program CCTG retweeted
⚠️ From press release on Skyscraper -06: Tira+Atezo +chemo INCREASED by 33% the risk of DEATH compared to Pembro +chemo 🤦🏻
Could ICI combos exert detrimental effect? More is NOT always better in IO and some ICI combos may have hetero-neutralizing impact on microenvironmental immune activation
IMO we should abandon “chemo+Pembro+ “another ICI” trials in unselected populations and try to define molecularly selected subsets( co-mutations?) of pts who require combinatorial approaches
#some #LCSM @OncoAlert @OncBrothers
IND Program CCTG retweeted
Come and join us! We are recruiting a fully funded PhD student to our @MRCTMRPDTP with @ChristinaBYap at ICR. Please share widely. Closing date 15 August. For more information see mrctmrpdtp.com/current-oppor…
ALT An image advertising a fully funded PhD project entitled design and analysis of early phase adaptive platform trials in the era of precision oncology. Based at the Institute of ICR. Closing date 15 August 2024. Project start date is October 2024 or soon thereafter.
IND Program CCTG retweeted
Great news for Horizon Europe and Canada, this will lead to a wealth of opportunities for collaborative research! 🇪🇺
🇪🇺🤝🇨🇦 It's official! The @EU_Commission and Canada are signing an agreement to enhance cooperation in science, technology and innovation under the Pilar II of #HorizonEU. #EUCanada
Read more: europa.eu/!48gNCy
IND Program CCTG retweeted
Retrospective look at impact of durvalumab on pneumonitis after chemoradiation for NSCLC @ClinicalLung. With durva, 57% G1 pneumonitis, 38% G2, 5% G3. Steroid course 17w with durva and 7w without. Pneumonitis relapse 23% with durvalumab, 7% without.
clinical-lung-cancer.com/art…
IND Program CCTG retweeted
Exercise and wellness have lots of advantages for people with cancer – before, during and after treatment.
The Canadian Cancer Society is proud to fund a wide range of research projects focused on encouraging exercise to improve the well-being of people living with or beyond cancer.
To read about the 5 projects we’re excited to highlight and the teams that are making this all happen, visit this link today: bit.ly/3xrYEYO
